These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 2040188)

  • 1. Erythropoietin and the myelodysplastic syndrome.
    Jacobs A; Culligan D; Bowen D
    Contrib Nephrol; 1991; 88():266-70. PubMed ID: 2040188
    [No Abstract]   [Full Text] [Related]  

  • 2. Recombinant human erythropoietin at high dose is effective for the treatment of the anemia of myelodysplastic syndromes.
    Laporte JP; Isnard F; Fenaux P; Woler M; Najman A
    Contrib Nephrol; 1991; 88():271-2; discussion 273-5. PubMed ID: 2040189
    [No Abstract]   [Full Text] [Related]  

  • 3. Improvement in anemia by recombinant human erythropoietin in patients with myelodysplastic syndrome and aplastic anemia.
    Hirashima K; Bessho M; Jinnai I
    Contrib Nephrol; 1991; 88():254-65. PubMed ID: 2040187
    [No Abstract]   [Full Text] [Related]  

  • 4. Clinical evaluation of erythropoietin (EPO) in oncology.
    Oster W; Schindel F; Heinrichs H
    Behring Inst Mitt; 1991 Dec; (90):62-8. PubMed ID: 1801692
    [No Abstract]   [Full Text] [Related]  

  • 5. Sustained resolution of anemia without any treatment after excessive therapeutic response to human recombinant erythropoietin in three patients with myelodysplastic syndromes.
    Niscola P; Tendas A; Giovannini M; Scaramucci L; Cupelli L; Catalano G; Perrotti A; de Fabritiis P
    Support Care Cancer; 2013 Jul; 21(7):1803-5. PubMed ID: 23604522
    [No Abstract]   [Full Text] [Related]  

  • 6. Use of a functional classification of anemia in myelodysplastic syndromes to identify subgroups of patients responsive to recombinant human-erythropoietin therapy.
    Bucalossi A; Marotta G; Bigazzi C; Galieni P; Vessihelli F; Falbo R; Dispensa E
    Eur J Haematol; 1996; 56(1-2):106-8. PubMed ID: 8599983
    [No Abstract]   [Full Text] [Related]  

  • 7. The role of erythropoietin in patients with anemia and normal renal function.
    Oster W; Mertelsmann R
    Contrib Nephrol; 1990; 87():26-35. PubMed ID: 2093538
    [No Abstract]   [Full Text] [Related]  

  • 8. Use of recombinant human erythropoietin to treat the anemia of myelodysplastic syndromes.
    Greenberg PL
    Semin Hematol; 1993 Oct; 30(4 Suppl 6):22-4. PubMed ID: 8153674
    [No Abstract]   [Full Text] [Related]  

  • 9. Clinical use of erythropoietic stimulating agents in myelodysplastic syndromes.
    Santini V
    Oncologist; 2011; 16 Suppl 3():35-42. PubMed ID: 21930833
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Darbepoetin alfa for anemia with myelodysplastic syndrome.
    Seastone DJ; Gerds AT
    Expert Rev Hematol; 2015 Apr; 8(2):139-46. PubMed ID: 25579702
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correction of anaemia with recombinant human erythropoietin.
    Ponticelli C; Casati S
    Nephron; 1989; 52(3):201-8. PubMed ID: 2662045
    [No Abstract]   [Full Text] [Related]  

  • 12. A good response rate to recombinant erythropoietin alone may be expected in selected myelodysplastic patients. A preliminary clinical study.
    Di Raimondo F; Longo G; Cacciola E; Milone G; Palumbo GA; Cacciola RR; Alessi M; Giustolisi R
    Eur J Haematol; 1996; 56(1-2):7-11. PubMed ID: 8599997
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Erythropoietin for anemia.
    Med Lett Drugs Ther; 1989 Sep; 31(801):85-6. PubMed ID: 2671624
    [No Abstract]   [Full Text] [Related]  

  • 14. Advances in conducting retrospective chart review studies: use of electronic report forms and database in a community study in anemic patients with myelodysplastic syndrome.
    Sullivan T; Mun Y; Wallace JF; Patton JF
    J Support Oncol; 2005; 3(6 Suppl 4):12-3. PubMed ID: 16355550
    [No Abstract]   [Full Text] [Related]  

  • 15. Erythropoietin in myelodysplastic syndromes: durable response in a young patient.
    Aloe Spiriti MA; Latagliata R; Petti MC
    Haematologica; 1996; 81(4):381-2. PubMed ID: 8870388
    [No Abstract]   [Full Text] [Related]  

  • 16. Recombinant erythropoietin in myelodysplastic syndromes: whom to treat and how? More questions than answers.
    Mittelman M
    Acta Haematol; 1993; 90(2):53-7. PubMed ID: 8285018
    [No Abstract]   [Full Text] [Related]  

  • 17. Therapy with human recombinant erythropoietin in patients with myelodysplastic syndromes.
    Razzano M; Caslini C; Cortelazzo S; Battistel V; Rambaldi A; Barbui T
    Br J Haematol; 1992 Aug; 81(4):628-30. PubMed ID: 1390262
    [No Abstract]   [Full Text] [Related]  

  • 18. Combined use of erythropoietin and G-CSF in the treatment of myelodysplastic syndromes.
    Haematologica; 1999 Dec; 84(12):1057. PubMed ID: 10586204
    [No Abstract]   [Full Text] [Related]  

  • 19. rhEPO treatment of anemia in uremic patients.
    Bommer J; Barth HP; Schwöbel B
    Contrib Nephrol; 1990; 87():59-67. PubMed ID: 2093542
    [No Abstract]   [Full Text] [Related]  

  • 20. [Phase II clinical study of recombinant human erythropoietin on the anemia of myelodysplastic syndrome].
    Urabe A; Mizoguchi H; Takaku F; Miyazaki T; Yachi A; Niitsu Y; Miura Y; Mutoh Y; Fujioka S; Nomura T
    Rinsho Ketsueki; 1993 Aug; 34(8):928-36. PubMed ID: 8411647
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.